Compare PBHC & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | CYPH |
|---|---|---|
| Founded | 1859 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 73.4M |
| IPO Year | 2014 | N/A |
| Metric | PBHC | CYPH |
|---|---|---|
| Price | $13.60 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3K | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 46.25 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $0.50 |
| 52 Week High | $16.20 | $3.70 |
| Indicator | PBHC | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 54.21 |
| Support Level | $13.43 | $0.87 |
| Resistance Level | $13.75 | $1.31 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 87.50 | 37.82 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.